• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    2/10/22 12:43:23 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    SC 13G/A 1 p22-0442sc13ga.htm HYPERFINE, INC

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Hyperfine, Inc.

    (formerly known as HealthCor Catalio Acquisition Corp.)

    (Name of Issuer)
     

    Class A Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    44916K106

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 44916K10613G/APage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empyrean Capital Overseas Master Fund, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ý

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 44916K10613G/APage 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empyrean Capital Partners, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ý

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

    CUSIP No. 44916K10613G/APage 4 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Amos Meron

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ý

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 44916K10613G/APage 5 of 8 Pages

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Hyperfine, Inc. (formerly known as HealthCor Catalio Acquisition Corp.) (the "Issuer").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at 351 New Whitfield Street, Guilford, Connecticut 06437.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i) Empyrean Capital Overseas Master Fund, Ltd. ("ECOMF"), a Cayman Islands exempted company, with respect to the Class A Common Stock (as defined in Item 2(d)) directly held by it;
       
      (ii) Empyrean Capital Partners, LP ("ECP"), a Delaware limited partnership, which serves as investment manager to ECOMF with respect to the Class A Common Stock directly held by ECOMF;
       
      (iii) Mr. Amos Meron, who serves as the managing member of Empyrean Capital, LLC, the general partner of ECP, with respect to the Class A Common Stock directly held by ECOMF.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of Class A Common Stock owned by another Reporting Person.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is c/o Empyrean Capital Partners, LP, 10250 Constellation Boulevard, Suite 2950, Los Angeles, CA 90067.

     

    Item 2(c). CITIZENSHIP:

     

      ECOMF - a Cayman Island exempted company
      ECP - a Delaware limited partnership
      Amos Meron - United States

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A common stock, $0.0001 par value per share (the "Class A Common Stock")

     

     

    CUSIP No. 44916K10613G/APage 6 of 8 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      44916K106

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ Investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    § 240.13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    § 240.13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                         

     

    Item 4. OWNERSHIP.

     

        The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

     

    CUSIP No. 44916K10613G/APage 7 of 8 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 44916K10613G/APage 8 of 8 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    DATED:  February 10, 2022  
       
      empyrean capital partners, lp
       
      By: /s/ C. Martin Meekins
      Name: C. Martin Meekins
      Title: Chief Operating Officer
       
       
      Empyrean Capital Overseas MASTER Fund, Ltd.
      By: Empyrean Capital Partners, LP,
      its Investment Manager
       
      By: /s/ C. Martin Meekins
      Name: C. Martin Meekins
      Title: Chief Operating Officer
       
      /s/ Amos Meron
      AMOS MERON
           

     

     

    Get the next $HYPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

      Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

      5/28/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hyperfine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

      8/11/22 6:32:27 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI initiated coverage on Hyperfine with a new price target

      Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

      5/31/22 7:16:51 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo initiated coverage on Hyperfine with a new price target

      Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

      4/14/22 7:32:25 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI

      Rafael O'Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced the appointments of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O'Halloran, PhD, as Vice President of Technology. These leadership additions were instrumental in the development of the recently FDA-cleared Optive AI™ software and the new, next-generation Swoop® scanner. Their work will greatly aid the rollout of this new technology globally and the d

      6/11/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

      This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their patients across multiple sites of care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software. This new system delivers the highest level of image quality, functionality, and usability to date, unlocking a new brain im

      6/2/25 8:15:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of Optive AI™ Software, Introducing the Most Substantial Image Quality Improvement Ever for the Swoop® System

      Latest Swoop® System software delivers a substantial leap in image quality for AI-powered portable MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced FDA clearance of its next-generation software. This tenth-generation release delivers a substantial leap in image quality for ultra-low-field MR imaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528571999/en/Comparison of Swoop® system FLAIR images showing current image quality and ne

      5/28/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wolterman Dan

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      6/6/25 4:01:04 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:26:31 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas was granted 300,000 shares, increasing direct ownership by 365% to 382,213 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:24:42 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    SEC Filings

    See more
    • SEC Form 8-K filed by Hyperfine Inc.

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/23/25 5:00:17 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/19/25 4:15:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Hyperfine Inc.

      424B5 - Hyperfine, Inc. (0001833769) (Filer)

      5/13/25 4:25:28 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

      3/4/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

      GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

      11/12/24 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hyperfine Inc.

      SC 13G - Hyperfine, Inc. (0001833769) (Subject)

      2/13/24 5:06:19 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      2/14/23 4:07:09 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      12/20/22 4:22:37 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care